Heron Therapeutics Inc vs Micron Technology, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while Micron Technology, Inc. trades at $913.49 (market cap $980.90B). The key difference: Micron Technology, Inc. is far larger — about 15957.4× Heron Therapeutics Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MU | |
|---|---|---|
Market Cap | $61.47M | $980.90B |
Sector | Health | Technology |
52-Week High | $1.49 | $1.21K |
52-Week Low | $0.32 | $115.79 |
Enterprise Value | $168.21M | $961.25B |
Dividend Yield | — | 0.06% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.
The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.
Micron Technology (MU) trades at $921.01, up 6.97% in 24 hours, with strong earnings beats in recent quarters and robust profitability metrics. Technical indicators show a bearish short-term signal, with the stock near resistance at $877. The company exhibits exceptional gross margins of 72.57% and net income margin of 55.91%, supported by surging memory demand and strategic customer agreements.
Outlook remains positive due to AI-driven memory demand and locked-in revenues, but risks include cyclical industry pressures and competitive threats. Analyst consensus is strongly bullish with an average price target of $1,540, suggesting significant upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →